دورية أكاديمية
Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
| العنوان: | Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study. |
|---|---|
| المؤلفون: | Yalçın TY; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Baskent University, Ankara, Turkey., Topçu DI; Faculty of Medicine, Biochemistry, Baskent University, Ankara, Turkey., Doğan Ö; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Koc University, Istanbul, Turkey., Aydın S; Department of Public Health, Faculty of Medicine, Ankara University, Ankara, Turkey., Sarı N; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Baskent University, Ankara, Turkey., Erol Ç; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Baskent University, Ankara, Turkey., Kuloğlu ZE; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Koc University, Istanbul, Turkey., Azap ÖK; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Baskent University, Ankara, Turkey., Can F; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Koc University, Istanbul, Turkey., Arslan H; Faculty of Medicine, Infectious Diseases and Clinical Microbiology, Baskent University, Ankara, Turkey. |
| المصدر: | Journal of medical virology [J Med Virol] 2022 Jan; Vol. 94 (1), pp. 279-286. Date of Electronic Publication: 2021 Sep 10. |
| نوع المنشور: | Journal Article; Observational Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7705876 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1096-9071 (Electronic) Linking ISSN: 01466615 NLM ISO Abbreviation: J Med Virol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York Ny : Wiley-Liss Original Publication: New York, Liss. |
| مواضيع طبية MeSH: | Antibodies, Neutralizing/*blood , Antibodies, Viral/*blood , COVID-19 Vaccines/*immunology , Immunogenicity, Vaccine/*immunology , SARS-CoV-2/*immunology , Vaccines, Inactivated/*immunology, Adult ; COVID-19/immunology ; COVID-19/prevention & control ; Comorbidity ; Female ; Health Personnel/statistics & numerical data ; Humans ; Immunization, Secondary ; Immunoglobulin G/blood ; Male ; Middle Aged ; Prospective Studies ; Vaccination ; Young Adult |
| مستخلص: | Vaccines have been seen as the most important solution for ending the coronavirus disease 2019 (COVID-19) pandemic. The aim of this study is to evaluate the antibody levels after inactivated virus vaccination. We included 148 healthcare workers (74 with prior COVID-19 infection and 74 with not). They received two doses of inactivated virus vaccine (CoronaVac). Serum samples were prospectively collected three times (Days 0, 28, 56). We measured SARS-CoV-2 IgGsp antibodies quantitatively and neutralizing antibodies. After the first dose, antibody responses did not develop in 64.8% of the participants without prior COVID-19 infection. All participants had developed antibody responses after the second dose. We observed that IgGsp antibody titers elicited by a single vaccine dose in participants with prior COVID-19 infection were higher than after two doses of vaccine in participants without prior infection (geometric mean titer: 898 and 607 AU/ml). IgGsp antibodies, participants with prior COVID-19 infection had higher antibody levels as geometric mean titers at all time points (p < 0.001). We also found a positive correlation between IgGsp antibody titers and neutralizing capacity (r (© 2021 Wiley Periodicals LLC.) |
| References: | J Clin Invest. 2020 Oct 1;130(10):5235-5244. (PMID: 32634129) JAMA. 2021 Apr 13;325(14):1467-1469. (PMID: 33646292) Clin Microbiol Infect. 2021 Oct;27(10):1516.e7-1516.e14. (PMID: 34111577) Lancet Infect Dis. 2021 Jun;21(6):803-812. (PMID: 33548194) Nat Med. 2021 Jun;27(6):981-984. (PMID: 33795870) Lancet Infect Dis. 2021 Aug;21(8):1071-1072. (PMID: 34051887) Lancet Infect Dis. 2021 Feb;21(2):181-192. (PMID: 33217362) Lancet. 2021 Mar 27;397(10280):1178-1181. (PMID: 33640037) N Engl J Med. 2021 Jun 17;384(24):2354-2356. (PMID: 33822491) Lancet. 2021 Jul 17;398(10296):213-222. (PMID: 34246358) J Med Virol. 2022 Jan;94(1):279-286. (PMID: 34468990) Clin Chem. 2021 Jan 30;67(2):404-414. (PMID: 33084854) Lancet. 2021 Apr 17;397(10283):1459-1469. (PMID: 33844963) Nat Med. 2021 Jul;27(7):1205-1211. (PMID: 34002089) Science. 2021 Feb 5;371(6529):. (PMID: 33408181) Signal Transduct Target Ther. 2020 Sep 2;5(1):180. (PMID: 32879307) Nat Commun. 2020 Sep 17;11(1):4704. (PMID: 32943637) Clin Microbiol Infect. 2021 Sep;27(9):1349.e1-1349.e6. (PMID: 33975009) |
| فهرسة مساهمة: | Keywords: SARS-CoV-2 antibody; coronaVac; immunogenicity; inactivated virus vaccine; neutralizing antibody |
| المشرفين على المادة: | 0 (Antibodies, Neutralizing) 0 (Antibodies, Viral) 0 (COVID-19 Vaccines) 0 (Immunoglobulin G) 0 (Vaccines, Inactivated) |
| تواريخ الأحداث: | Date Created: 20210901 Date Completed: 20211123 Latest Revision: 20211211 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC8661640 |
| DOI: | 10.1002/jmv.27316 |
| PMID: | 34468990 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1096-9071 |
|---|---|
| DOI: | 10.1002/jmv.27316 |